Literature DB >> 28689299

4-O'-methylhonokiol protects from alcohol/carbon tetrachloride-induced liver injury in mice.

Eleonora Patsenker1,2, Andrea Chicca3, Vanessa Petrucci3, Sheida Moghadamrad4, Andrea de Gottardi4,5, Jochen Hampe6, Jürg Gertsch3, Nasser Semmo4,5, Felix Stickel7.   

Abstract

Alcoholic liver disease (ALD) is a leading cause of liver cirrhosis, liver cancer, and related mortality. The endocannabinoid system contributes to the development of chronic liver diseases, where cannabinoid receptor 2 (CB2) has been shown to have a protecting role. Thus, here, we investigated how CB2 agonism by 4'-O-methylhonokiol (MHK), a biphenyl from Magnolia grandiflora, affects chronic alcohol-induced liver fibrosis and damage in mice. A combination of alcohol (10% vol/vol) and CCl4 (1 ml/kg) was applied to C57BL/6 mice for 5 weeks. MHK (5 mg/kg) was administered daily, and liver damage assessed by serum AST and ALT levels, histology, gene, and protein expression. Endocannabinoids (ECs) and related lipid derivatives were measured by liquid chromatography and mass spectrometry (LC-MS) in liver tissues. In vitro, MHK was studied in TGFβ1-activated hepatic stellate cells (HSC). MHK treatment alleviated hepatic fibrosis, paralleled by induced expression of matrix metalloproteinases (MMP)-2, -3, -9, and -13, and downregulation of CB1 mRNA. Necrotic lesions and hepatic inflammation were moderately improved, while IL-10 mRNA increased and IFNγ, Mcl-1, JNK1, and RIPK1 normalized by MHK. Hepatic anandamide (AEA) and related N-acetylethanolamines (NAEs) were elevated in MHK group, whereas fatty acid synthase and diacylglycerol O-acyltransferase 2 expression reduced. In vitro, MHK prevented HSC activation and induced apoptosis via induction of bak1 and bcl-2. To conclude, MHK revealed hepatoprotective effects during alcohol-induced liver damage through the induction of MMPs, AEA, and NAEs and prevention of HSC activation, indicating MHK as a potent therapeutic for liver fibrosis and ALD. KEY MESSAGES: Methylhonokiol improves liver damage and survival. Methylhonokiol reduces hepatic fibrosis and necroinflammation. Methylhonokiol prevents myofibroblast activation and induces apoptosis. Methylhonokiol upregulates endocannabinoids and related N-acylethanolamines. Methylhonokiol contributes to lipid hydrolysis via PPARα/γ.

Entities:  

Keywords:  Alcohol; Cannabinoids; Liver; Methylhonokiol; Therapy

Mesh:

Substances:

Year:  2017        PMID: 28689299     DOI: 10.1007/s00109-017-1556-y

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  50 in total

1.  Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis.

Authors:  Mohanraj Rajesh; Hao Pan; Partha Mukhopadhyay; Sándor Bátkai; Douglas Osei-Hyiaman; György Haskó; Lucas Liaudet; Bin Gao; Pál Pacher
Journal:  J Leukoc Biol       Date:  2007-07-25       Impact factor: 4.962

2.  Magnolia officinalis attenuates free fatty acid-induced lipogenesis via AMPK phosphorylation in hepatocytes.

Authors:  Min Suk Seo; Sung-Woon Hong; Sung Hum Yeon; Young-Mok Kim; Key An Um; Jung Hwan Kim; Hye Jung Kim; Ki Churl Chang; Sang Won Park
Journal:  J Ethnopharmacol       Date:  2014-09-28       Impact factor: 4.360

3.  4-O-methylhonokiol attenuated β-amyloid-induced memory impairment through reduction of oxidative damages via inactivation of p38 MAP kinase.

Authors:  Yong Kyung Lee; Im Seop Choi; Jung Ok Ban; Hwa Jeong Lee; Ung Soo Lee; Sang Bae Han; Jae Kyung Jung; Young Hee Kim; Ki Ho Kim; Ki-Wan Oh; Jin Tae Hong
Journal:  J Nutr Biochem       Date:  2010-08-05       Impact factor: 6.048

4.  Cannabinoid receptor type I modulates alcohol-induced liver fibrosis.

Authors:  Eleonora Patsenker; Matthias Stoll; Gunda Millonig; Abbas Agaimy; Till Wissniowski; Vreni Schneider; Sebastian Mueller; Rudolf Brenneisen; Helmut K Seitz; Matthias Ocker; Felix Stickel
Journal:  Mol Med       Date:  2011-08-19       Impact factor: 6.354

Review 5.  Endocannabinoids in liver disease.

Authors:  Joseph Tam; Jie Liu; Bani Mukhopadhyay; Resat Cinar; Grzegorz Godlewski; George Kunos
Journal:  Hepatology       Date:  2011-01       Impact factor: 17.425

Review 6.  Animal models of alcoholic liver disease.

Authors:  Gavin E Arteel
Journal:  Dig Dis       Date:  2011-04-27       Impact factor: 2.404

7.  Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry).

Authors:  P Burra; M Senzolo; R Adam; V Delvart; V Karam; G Germani; J Neuberger
Journal:  Am J Transplant       Date:  2009-12-01       Impact factor: 8.086

8.  Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis.

Authors:  Justine E Roderick; Nicole Hermance; Matija Zelic; Matthew J Simmons; Apostolos Polykratis; Manolis Pasparakis; Michelle A Kelliher
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-22       Impact factor: 11.205

9.  Synthesis and pharmacological evaluation of new biphenylic derivatives as CB2 receptor ligands.

Authors:  Simone Bertini; Andrea Chicca; Chiara Arena; Stefano Chicca; Giuseppe Saccomanni; Jürg Gertsch; Clementina Manera; Marco Macchia
Journal:  Eur J Med Chem       Date:  2016-03-30       Impact factor: 6.514

10.  BL153 partially prevents high-fat diet induced liver damage probably via inhibition of lipid accumulation, inflammation, and oxidative stress.

Authors:  Jian Wang; Chi Zhang; Zhiguo Zhang; Qiang Chen; Xuemian Lu; Minglong Shao; Liangmiao Chen; Hong Yang; Fangfang Zhang; Peng Cheng; Yi Tan; Ki-Soo Kim; Ki Ho Kim; Bochu Wang; Young Heui Kim
Journal:  Oxid Med Cell Longev       Date:  2014-04-03       Impact factor: 6.543

View more
  1 in total

Review 1.  Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System.

Authors:  Ana Lago-Fernandez; Sara Zarzo-Arias; Nadine Jagerovic; Paula Morales
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.